PTN - Palatin Technologies Inc Stock Price, Fair Value and News

1.85USD-0.07 (-3.65%)Market Closed

Market Summary

USD1.85-0.07

Market Closed

-3.65%

PTN Alerts

1 major insider buys recently.

PTN Stock Price

View Fullscreen

PTN RSI Chart

PTN Valuation

Market Cap

29.9M

Price/Earnings (Trailing)

-0.89

Price/Sales (Trailing)

4.21

EV/EBITDA

-0.75

Price/Free Cashflow

-1.12

PTN Price/Sales (Trailing)

PTN Profitability

Operating Margin

96.02%

EBT Margin

-389.90%

Return on Equity

295.67%

Return on Assets

-248.33%

Free Cashflow Yield

-89.61%

PTN Fundamentals

PTN Revenue

Revenue (TTM)

7.1M

Rev. Growth (Yr)

98.18%

Rev. Growth (Qtr)

-3.41%

PTN Earnings

Earnings (TTM)

-33.7M

Earnings Growth (Yr)

-389.72%

Earnings Growth (Qtr)

-33.21%

Breaking Down PTN Revenue

Last 7 days

-8.4%

Last 30 days

20.1%

Last 90 days

-35.8%

Trailing 12 Months

-30.2%

How does PTN drawdown profile look like?

PTN Financial Health

Current Ratio

1.09

PTN Investor Care

Shares Dilution (1Y)

44.69%

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	3.9M	4.9M	6.1M	7.1M
2022	1.2M	1.5M	2.2M	2.9M
2021	343.1K	568.1K	793.2K	1.0M
2020	15.2M	118.0K	0	0
2019	62.0M	60.3M	45.3M	30.2M
2018	67.1M	67.1M	65.4M	63.7M
2017	40.0M	67.1M	67.1M	67.1M
2015	10.8M	13.0M	0	0
2014	0	0	6.5M	8.6M
2013	2.2M	4.3M	0	0
2012	424.2K	73.7K	50.8K	45.4K
2011	0	1.5M	1.1M	774.6K
2010	0	0	0	0

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Palatin Technologies Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 11, 2024	deveer robert k jr	bought	12,703	2.1172	6,000	-
Mar 06, 2024	deveer robert k jr	sold	-23,433	2.00288	-11,700	-
Dec 06, 2023	wills stephen t	sold	-12,563	2.51363	-4,998	executive vp and cfo/coo
Dec 04, 2023	dunton alan w	sold	-495	2.4799	-200	-
Aug 15, 2023	wills stephen t	sold (taxes)	-17,907	2.21412	-8,088	executive vp and cfo/coo
Aug 15, 2023	spana carl	sold (taxes)	-27,155	2.21391	-12,266	president and ceo
Jun 20, 2023	wills stephen t	acquired	-	-	69,366	executive vp and cfo/coo
Jun 20, 2023	spana carl	acquired	-	-	79,605	president and ceo
Jun 20, 2023	manning anthony m.	acquired	-	-	10,000	-
Jun 20, 2023	dunton alan w	acquired	-	-	10,000	-

Which funds bought or sold PTN recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 12, 2024	Pacifica Partners Inc.	unchanged	-	-159	294	-%
Apr 11, 2024	SALEM INVESTMENT COUNSELORS INC	unchanged	-	-12.00	12.00	-%
Mar 11, 2024	VANGUARD GROUP INC	added	43.41	1,605,860	2,183,520	-%
Feb 14, 2024	DIVIDEND ASSETS CAPITAL, LLC	unchanged	-	-	-	-%
Feb 14, 2024	Fortress Investment Group LLC	unchanged	-	869	1,401	-%
Feb 14, 2024	CITADEL ADVISORS LLC	reduced	-93.62	-13,547	2,738	-%
Feb 14, 2024	Royal Bank of Canada	reduced	-65.09	-	-	-%
Feb 14, 2024	BRIDGEWAY CAPITAL MANAGEMENT, LLC	unchanged	-	64,527	103,974	-%
Feb 14, 2024	HOLLENCREST CAPITAL MANAGEMENT	unchanged	-	2.00	4.00	-%

Are Funds Buying or Selling PTN?

Are funds buying PTN calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own PTN

No. of Funds

PTN Alerts

1 major insider buys recently.

Unveiling Palatin Technologies Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	armistice capital, llc	4.99%	720,329	SC 13G/A
Feb 14, 2023	armistice capital, llc	9.99%	1,055,206	SC 13G
Jul 10, 2020	blackrock inc.	1.6%	3,736,787	SC 13G/A
Feb 05, 2020	blackrock inc.	6.9%	15,743,167	SC 13G/A

Recent SEC filings of Palatin Technologies Inc

View All Filings

Date Filed	Form Type	Document
Apr 11, 2024	4	Insider Trading
Mar 28, 2024	424B3	Prospectus Filed
Mar 28, 2024	EFFECT	EFFECT
Mar 14, 2024	S-1	Initial Public Offering
Mar 07, 2024	4	Insider Trading
Mar 04, 2024	144	Notice of Insider Sale Intent
Feb 15, 2024	8-K	Current Report
Feb 14, 2024	SC 13G/A	Major Ownership Report
Feb 14, 2024	10-Q	Quarterly Report
Feb 01, 2024	8-K	Current Report

Peers (Alternatives to Palatin Technologies Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	39.7B	6.8B	0.01%	-33.89%	-8.42	5.79	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.6B	1.8B	-1.06%	-27.57%	-42.25	10.17	76.23%	61.08%
BMRN	17.3B	2.4B	9.12%	-7.56%	103	7.14	15.42%	18.43%
INCY	12.0B	3.7B	-8.48%	-28.30%	20.07	3.25	8.87%	75.42%
MID-CAP
APLS	6.2B	396.6M	-9.27%	-36.41%	-11.74	15.65	425.83%	18.94%
BBIO	4.5B	-	-6.46%	74.90%	-6.94	60.35	54.84%	-34.79%
AXSM	3.2B	270.6M	-9.62%	-0.34%	-13.52	11.95	440.80%	-27.84%
ARWR	3.0B	240.7M	-15.06%	-21.14%	-10.03	12.36	-1.03%	-92.09%
ACAD	2.8B	726.4M	-8.60%	-6.11%	-45.41	3.83	40.45%	71.62%
SMALL-CAP
CPRX	1.8B	398.2M	-4.17%	-12.95%	25.42	4.56	85.90%	-14.05%
NVAX	576.6M	983.7M	-22.12%	-55.02%	-1.06	0.59	-50.36%	17.16%
CRBP	448.6M	881.7K	-2.13%	345.78%	-10.06	466.16	-77.61%	-5.33%
INO	256.8M	4.9M	2.33%	7.75%	-1.9	52.78	-54.97%	51.72%
IBIO	6.7M	2.1M	82.86%	81.13%	-0.25	2.14	-13.45%	66.37%

Palatin Technologies Inc News

Latest updates

Palatin Technologies Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3	2018Q2
Revenue	-3.4%	2,034,113	2,105,977	1,761,933	1,195,675	1,026,416	869,654	770,738	216,097	322,140	159,482	124,112	88,741	-	10,305	20,610	30,142,805	60,265,000	50,353,347	40,441,694	30,530,041	20,618,388
Cost Of Revenue	-	97,637	-	-	-	98,707	86,496	-	-	-	53,933	37,800	55,440	-	-	-	-	-	-	-	-	-
Operating Expenses	-89.5%	860,968	8,214,874	12,580,031	8,496,938	6,613,267	9,622,325	13,871,828	8,036,510	8,773,328	7,375,239	13,877,926	6,574,985	7,390,000	5,713,282	5,661,717	4,959,931	8,080,000	5,763,000	5,050,000	5,663,000	8,349
S&GA Expenses	-5.2%	3,032,613	3,200,244	5,070,318	3,537,376	3,174,344	3,508,798	-10,012,835	3,009,528	3,317,760	3,836,542	5,950,339	4,010,055	3,456,805	2,072,032	2,404,093	1,832,442	3,751,118	1,818,796	2,088,565	2,040,582	3,060,910
R&D Expenses	10.8%	5,554,200	5,014,630	7,405,681	4,830,327	4,367,538	6,027,031	7,436,199	4,980,074	5,426,397	3,484,764	3,481,800	2,509,490	3,933,034	3,641,250	3,257,624	3,127,489	4,328,766	3,943,982	2,961,656	3,622,691	5,288,387
EBITDA Margin	-Infinity%	-3.85	-	-6.57	-9.30	-12.47	-16.52	-24.54	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Interest Expenses	-85.3%	1,605	10,882	1,490	3,434	5,487	9,602	18,259	3,019	2,773	5,631	14,080	-	8,310	278	2,502	9,051	46,580	71,812	92,298	206,871	-90,865
Income Taxes	-	-	-	9,349,998	-	4,674,999	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	276
Earnings Before Taxes	-Infinity%	-7,844,034	-	-10,714,463	-7,147,919	-1,967,553	-	-15,282,425	-7,631,586	-	-	-	-	-	-	-	-	-	-5,727,130	-5,042,350	-5,682,056	-
EBT Margin	-Infinity%	-3.90	-	-6.64	-9.37	-12.56	-16.62	-24.65	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income	-33.2%	-7,844,034	-5,888,399	-12,780,234	-7,147,919	2,707,446	-8,255,408	-12,767,618	-7,631,586	-8,686,476	-7,112,619	-13,934,284	-5,729,660	-7,299,000	-5,382,275	-5,243,627	-4,500,949	52,224,000	-5,727,000	-5,042,000	-5,682,000	11,807
Net Income Margin	-25.0%	-4.74	-3.79	-5.67	-7.66	-10.43	-17.14	-24.65	-316	-300	-311	-284	-228	-	-	-	-	-	-	-	-	-
Free Cashflow	-78.0%	-10,513,301	-5,906,393	-9,658,160	-1,525,192	-8,947,028	-8,722,548	-7,755,964	-9,568,884	-12,599,158	-260,117	14,017,960	-3,510,189	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	20.5%	14.00	11.00	18.00	26.00	32.00	28.00	36.00	44.00	53.00	60.00	67.00	81.00	87.00	101	85.00	90.00	93.00	98.00	105	21.00	26.00
Current Assets	24.9%	12.00	10.00	16.00	24.00	31.00	26.00	35.00	42.00	51.00	58.00	66.00	79.00	85.00	100	84.00	90.00	92.00	97.00	104	21.00	25.00
Cash Equivalents	71.7%	9.00	6.00	8.00	20.00	21.00	21.00	30.00	38.00	47.00	53.00	60.00	69.00	72.00	87.00	83.00	89.00	91.00	97.00	44.00	20.00	25.00
Inventory	-100.0%	-	2.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	6.00	6.00	6.00	-	-	-	-	-	-	-
Net PPE	-7.9%	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Liabilities	51.9%	25.00	16.00	20.00	16.00	16.00	19.00	20.00	16.00	18.00	17.00	18.00	18.00	19.00	24.00	5.00	3.00	1.00	2.00	4.00	5.00	5.00
Current Liabilities	-17.7%	11.00	14.00	15.00	12.00	11.00	16.00	16.00	12.00	14.00	10.00	11.00	10.00	7.00	13.00	4.00	3.00	1.00	-	4.00	5.00	5.00
Long Term Debt	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
LT Debt, Non Current	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Shareholder's Equity	-80.1%	-11.38	-6.32	0.00	10.00	12.00	8.00	16.00	28.00	35.00	43.00	50.00	63.00	68.00	77.00	80.00	87.00	91.00	96.00	101	16.00	21.00
Retained Earnings	-0.9%	-425	-421	-412	-404	-397	-396	-387	-375	-367	-358	-351	-337	-332	-322	-318	-310	-305	-300	-295	-348	-342
Additional Paid-In Capital	-0.7%	414	416	410	414	414	405	404	401	400	400	401	398	398	397	396	395	395	394	394	362	361
Shares Outstanding	19.7%	14.00	12.00	12.00	11.00	9.00	9.00	9.00	9.00	9.00	9.00	9.00	9.00	9.00	-	-	-	-	-	-	-	-
Float	-	-	-	-	-	26.00	-	-	-	116	-	-	-	156	-	-	-	177	-	-	-	142

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	-77.4%	-10,475	-5,906	-9,605	-555	-9,675	-8,581	-7,718	-9,491	-12,510	-202	14,018	-3,504	-14,420	3,813	-6,076	-2,512	-4,922	54,837	-6,945	-3,808	-5,491
Share Based Compensation	40.9%	550	390	222	397	619	437	716	534	623	633	709	775	863	821	804	702	805	828	615	654	979
Cashflow From Investing	216.2%	9,462	2,993	-3,045	-116	-123	-141	-37.12	-77.40	-89.10	-57.76	-1*	-5.72	-	-	-	-	-	-62.88	-	-36.14	-
Cashflow From Financing	1008.0%	4,974	449	1,008	-877	9,790	-24.73	-24.41	-37.13	6,504	-6,423	-22,554	-4.61	-11.26	-77.77	-18.63	-	-316	-1,586	30,642	-1,000	-2,469

PTN Income Statement

2023-12-31

Consolidated Statements of Operations (unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2023	Dec. 31, 2022
REVENUES
Product revenue, net	$ 2,034,113	$ 1,026,416	$ 4,140,090	$ 1,896,070
OPERATING EXPENSES
Cost of products sold	97,637	98,707	97,637	185,203
Research and development	5,554,200	4,367,538	10,568,830	10,394,569
Selling, general and administrative	3,032,613	3,174,344	6,232,857	6,683,142
Gain on sale of Vyleesi	(7,823,482)	0	(7,823,482)	0
Gain on purchase commitment	0	(1,027,322)	0	(1,027,322)
Total operating expenses	860,968	6,613,267	9,075,842	16,235,592
Income (loss) from operations	1,173,145	(5,586,851)	(4,935,752)	(14,339,522)
OTHER INCOME (EXPENSE)
Investment income	62,026	186,473	133,656	274,962
Foreign currency (loss) gain	(306,697)	(693,231)	(146,947)	(274,855)
Interest expense	(1,605)	(5,487)	(12,487)	(15,089)
Offering expenses	(696,912)	(1,115,765)	(696,912)	(1,115,765)
Change in fair value of warrant liabilities	(8,073,991)	5,247,308	(7,391,591)	5,247,308
Total other income (expense), net	(9,017,179)	3,619,298	(8,114,281)	4,116,561
(Loss) Income before income taxes	(7,844,034)	(1,967,553)	(13,050,033)	(10,222,961)
Income tax benefit	0	4,674,999	0	4,674,999
NET (LOSS) INCOME	$ (7,844,034)	$ 2,707,446	$ (13,050,033)	$ (5,547,962)
Basic and diluted net (loss) income per common share	$ (0.56)	$ 0.25	$ (0.99)	$ (0.54)
Weighted average number of common shares outstanding used in computing basic and diluted net (loss) income per common share	14,097,757	10,802,863	13,134,228	10,215,616

PTN Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($)	Dec. 31, 2023	Jun. 30, 2023
Current assets:
Cash and cash equivalents	$ 9,485,252	$ 7,989,582
Marketable securities	0	2,992,890
Accounts receivable	2,346,163	2,915,760
Inventories	0	526,000
Prepaid expenses and other current assets	413,954	1,897,281
Total current assets	12,245,369	16,321,513
Property and equipment, net	550,465	684,910
Right-of-use assets - operating leases	702,003	876,101
Other assets	56,916	56,916
Total assets	13,554,753	17,939,440
Current liabilities:
Accounts payable	1,593,476	4,303,527
Accrued expenses	5,614,247	6,511,059
Short-term operating lease liabilities	363,718	354,052
Short-term finance lease liabilities	99,912	106,392
Other current liabilities	3,528,050	3,856,800
Total current liabilities	11,199,403	15,131,830
Long-term operating lease liabilities	357,744	544,323
Long-term finance lease liabilities	0	46,014
Other long-term liabilities	1,106,700	2,083,200
Warrant liabilities	11,852,232	1,850,544
Total liabilities	24,516,079	19,655,911
Commitments and contingencies (Note 13)
Contingently redeemable warrants	423,100	263,400
Stockholders' deficiency:
Preferred stock of $0.01 par value - authorized 10,000,000 shares: shares issued and outstanding designated as follows:Series A Convertible: authorized 4,030 shares as of December 31, 2023: issued and outstanding 4,030 shares as of December 31, 2023 and June 30, 2023	40	40
Common stock of $0.01 par value - authorized 300,000,000 shares:issued and outstanding 14,305,137 shares as of December 31, 2023 and 11,656,714 shares as of June 30, 2023	143,051	116,567
Additional paid-in capital	413,552,953	409,933,959
Accumulated deficit	(425,080,470)	(412,030,437)
Total stockholders' deficiency	(11,384,426)	(1,979,871)
Total liabilities and stockholders' deficiency	$ 13,554,753	$ 17,939,440

About Palatin Technologies Inc

Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that has completed Phase I clinical trial for the treatment of inflammatory bowel diseases. In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease; and melanocortin peptides for diabetic retinopathy. Further, it is developing PL3994, a peptide mimetic molecule with amino acid mimetic structure and amino acids properties; and L8177, an oral peptide formulation for treatment of ulcerative colitis, which entered Phase 2 clinical trials. The company was founded in 1986 and is based in Cranbury, New Jersey.

CEO	Dr. Carl Spana Ph.D.
WEBSITE	https://palatin.com
INDUSTRY	Biotechnology
EMPLOYEES	33

Palatin Technologies Inc Frequently Asked Questions

What is the ticker symbol for Palatin Technologies Inc? What does PTN stand for in stocks?

PTN is the stock ticker symbol of Palatin Technologies Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Palatin Technologies Inc (PTN)?

As of Mon Apr 15 2024, market cap of Palatin Technologies Inc is 29.85 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of PTN stock?

You can check PTN's fair value in chart for subscribers.

What is the fair value of PTN stock?

You can check PTN's fair value in chart for subscribers. The fair value of Palatin Technologies Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Palatin Technologies Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for PTN so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Palatin Technologies Inc a good stock to buy?

The fair value guage provides a quick view whether PTN is over valued or under valued. Whether Palatin Technologies Inc is cheap or expensive depends on the assumptions which impact Palatin Technologies Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for PTN.

What is Palatin Technologies Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Mon Apr 15 2024, PTN's PE ratio (Price to Earnings) is -0.89 and Price to Sales (PS) ratio is 4.21. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. PTN PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Palatin Technologies Inc's stock?

In the past 10 years, Palatin Technologies Inc has provided -0.238 (multiply by 100 for percentage) rate of return.